JNCE Jounce Therapeutics Inc.

6.2
+0.19  (+3%)
Previous Close 6.01
Open 6.03
Price To Book 1.96
Market Cap 204428539
Shares 32,972,345
Volume 152,487
Short Ratio
Av. Daily Volume 248,660

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data at AACR - poster April 2, 2019 1pm.
JTX-2011
Solid tumors - Cancer
Phase 1 enrolment of first cohort completed - January 3, 2019.
JTX-4014
Solid tumors

Latest News

  1. Investors Who Bought Jounce Therapeutics (NASDAQ:JNCE) Shares A Year Ago Are Now Down 80%
  2. Edited Transcript of JNCE.O earnings conference call or presentation 6-Mar-19 1:00pm GMT
  3. Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
  4. Jounce Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference
  5. Jounce Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Wednesday, March 6, 2019
  6. Jounce Therapeutics to Present Data from its JTX-2011 and JTX-8064 Programs at the 2019 American Association for Cancer Research (AACR) Annual Meeting
  7. In-house lawyers demand diversity, but their own boards lack women
  8. Edited Transcript of JNCE.O earnings conference call or presentation 13-Nov-18 1:00pm GMT
  9. Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014
  10. Jounce Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
  11. Hedge Funds Are Crazy About Jounce Therapeutics, Inc. (JNCE)
  12. Report: Exploring Fundamental Drivers Behind Matrix Service, NantHealth, Earthstone Energy, Jounce Therapeutics, BeiGene, and Oxford Immunotec Global — New Horizons, Emerging Trends, and Upcoming Developments
  13. Jounce Therapeutics, Inc. (JNCE) Reports Q3 Loss, Tops Revenue Estimates
  14. Jounce Therapeutics Reports Third Quarter 2018 Financial Results
  15. Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
  16. Jounce Therapeutics to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 13, 2018
  17. Analysts Estimate Jounce Therapeutics, Inc. (JNCE) to Report a Decline in Earnings: What to Look Out for
  18. Jounce Therapeutics to Present Two Posters from the JTX-2011 Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting